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We conducted a phase II trial of gemcitabine with S-1, oral fluorouracil (5-FU) prodrug tegafur combined with two modulators,
5-chloro-2, 4-dihydroxypyridine and potassium oxonate, to evaluate the activity and toxicity of such a combination in metastatic
pancreatic cancer (MPC) patients. Patients who had pathologically proven pancreatic cancer with metastatic lesions were eligible
candidates for entry into the study. S-1 was given orally (30mgm
 2) b.i.d. for 14 consecutive days and gemcitabine (1000mgm
 2)
was given on days 8 and 15. The cycle was repeated every 21 days. We enrolled 33 MPC patients. The median number of cycles was
eight (range 1–20). Grade 3–4 toxicities were leucopenia (33%), neutropenia (55%), anaemia (9%), thrombocytopenia (15%),
anorexia (6%), fever (9%), and interstitial pneumonia (6%). Objective responses were obtained in 16 patients (one complete
response and 15 partial responses; response rate, 48%; 95% confidence interval (CI), 33–65). Median survival and 1-year survival rate
were 12.5 months (95% CI, 5.9–19.1) and 54% (95% CI, 36–72), respectively. Combination chemotherapy with GEM and S-1 was
well tolerated and yielded a significantly high response rate.
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Pancreatic cancer is one of the most frequently observed
gastrointestinal cancers and its prognosis remains extremely
dismal. It is the fifth leading cause of cancer death in Japan, as
well as in the US and European countries (Matsuno et al, 2004).
The 5-year survival rate is still poor, at less than 10%, which is
commonly considered to be linked to the high incidence of
metastatic disease even on initial diagnosis, as well as the relative
chemoresistance of this tumour. Therefore, innovations in
systemic chemotherapy are needed to improve the survival of
patients with advanced pancreatic cancer (APC) (Glimelius et al,
1996; Evans et al, 1997).
Over the past few years, gemcitabine has been the most widely
used chemotherapeutic agent in APC and was reported to yield
significantly better symptom control of APC than 5-FU in a
randomised phase III clinical study (Burris et al, 1997). However,
the activity of gemcitabine in pancreatic cancer remains modest
and there is a clear need to improve its efficacy by combining it
with other anticancer drugs.
Chemotherapy combinations for the treatment of pancreatic
cancer could involve prolonged or continuous infusion of 5-FU,
because the combination of gemcitabine and 5-FU is shown to
have a marked synergistic cytotoxic effect against pancreatic
cancer cells in in vitro assay (Bruckner et al, 1998). Oral
administration of 5-FU is not effective, owing to the inability to
achieve plasma concentration of sufficient magnitude. An inter-
esting way to increase the efficacy of 5-FU is through the inhibition
of the degrading enzyme, dihydropyrimidine dehydrogenase
(DPD).
S-1 is a new oral fluorinated pyrimidine developed by Taiho
Pharmaceutical Co Ltd (Tokyo, Japan). The agent contains tegafur
(FT), 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium
oxonate (Oxo) in a molar ratio of FT : CDHP: Oxo¼1:0.4:1,
based on the biochemical modulation of 5-FU (Shirasaka et al,
1996a,b). Tegafur, a prodrug of 5-FU, is gradually converted to
5-FU and is rapidly catabolised by DPD in the liver. 5-chloro-2,
4-dihydroxypyridine is a competitive inhibitor of 5-FU catabolism,
being about 180 times more potent than uracil in inhibiting DPD
(Tatsumi et al, 1987). When combined with 5-FU, this results in
the prolonged maintenance of 5-FU concentrations, both in plasma
and in tumours. In addition, it has been suggested that CDHP has
the potential to enhance the antitumour activity of 5-FU against
subcutaneous tumours in nude mice, using human pancreas
carcinoma cells with a high tumoural DPD activity (Takechi et al,
2002). Oxo is an agent that decreases the phosphorylation of 5-FU
in the gastrointestinal tract by inhibiting the enzyme pyrimidine
phosphoribosyl transferase. Oxo preferentially localises in the gut
rather than in the tumour and has a potential biochemical effect on
the enzyme pyrimidine phosphoribosyl transferase, thereby
selectively inhibiting the formation of 5-FU nucleotides in the
gut and theoretically reducing gastrointestinal side effects (Takechi
et al, 1997).
S-1 has undergone phase I evaluation in Japan, as well as
extensive phase II studies in gastric, colon, head and neck and
breast cancers, leading to registration in this country for gastric
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scancer. In phase II studies for advanced gastric cancer conducted
in Japan, S-1 showed high response rates of 44–49% (Sakata et al,
1998; Koizumi et al, 2000). In studies outside of Japan, the phase II
studies of S-1 against gastric (Chollet et al, 2003) and colorectal
cancer (Van den Brande et al, 2003) in Europe by the EORTC-Early
Clinical Study Group revealed moderate activity. The antitumour
activity of S-1 in patients with pancreatic cancer has not yet been
investigated outside Japan, but favourable results of S-1 mono-
therapy have been reported in Japanese early phase II and late
phase II studies of patients with APC (Furuse et al, 2005; Ueno
et al, 2005).
The administration of oral S-1 is more convenient and simulates
the effect of continuous infusion of 5-FU. The combination of
gemcitabine and 5-FU is shown to have a marked synergistic
cytotoxic effect against pancreatic cancer cells in in vitro assay
(Bruckner et al, 1998). We anticipated that combination chemo-
therapy of gemcitabine and S-1 would be effective through the
synergistic activity of gemcitabine and 5-FU derived from S-1.
Thus, we performed a phase I study to evaluate the safety of
treatment combining GEM with S-1 and to determine the MTD of
each drug in patients with APC (Nakamura et al, 2005). This
combination chemotherapy was well tolerated and showed out-
standing antitumour activity.
Therefore we conducted a phase II study of this combination
chemotherapy in patients with metastatic pancreatic cancer (MPC)
and assessed the efficacy and toxicity of this regimen.
PATIENTS AND METHODS
End point
The primary end point of this study was to determine the efficacy
of a combination of gemcitabine and S-1 in MPC. The secondary
end points were to assess toxicity, time to progression, and
survival.
Patient selection
Patients with histopathologically proven APC with distant
metastasis were eligible for the study. Other eligibility criteria
included: 20–74 years of age, Eastern Cooperative Oncology Group
(ECOG) performance status of 2 or less (ambulatory and capable of
self-care), estimated life expectancy of more than 2 months,
adequate renal function (normal serum creatinine and blood urea
nitrogen levels), liver function (total bilirubin level p2.5 times
upper normal limit (UNL) or p3 times UNL after biliary drainage
if the patient had obstructive jaundice and serum transaminases
(GOT, GPT) levels p2.5 times UNL or p3 times UNL), bone
marrow reserve (white blood cell count between 4000 and
12000mm
 3, neutrophil count X2000mm
 3, platelet count
X100000mm
 3 and haemoglobin level X9.5gdl
 1) and pulmon-
ary function (PaO2 X70mmHg). If the patients had a previous
history of cancer treatment, that treatment (tumour resection,
chemotherapy, immunotherapy, or radiotherapy) had to have been
discontinued for at least 4 weeks before entry into the study. All
subjects provided written informed consent.
The exclusion criteria were as follows: pulmonary fibrosis or
interstitial pneumonia, marked pericardial effusion, severe heart
disease, difficult to control diabetes mellitus, active infection,
pregnant or lactating women, women of childbearing age unless
using effective contraception, severe drug hypersensitivity, meta-
stases to the central nervous system, severe neurological impair-
ment or mental disorder, active concomitant malignancy, and
other serious medical conditions. The patients that have pancreatic
cancer with neuroendocrine characteristics were excluded.
This study was approved by the institutional review board of
Chiba University Graduate School of Medicine.
Treatment plan
We gave orally 30mgm
 2 S-1 twice daily, after breakfast and
dinner for 14 consecutive days (from the evening of day 1 to the
morning of day 15) followed by a 1-week break. Each capsule of
S-1 contained 20 or 25mg of FT. Individual doses were rounded
down to the nearest pill size less than the calculated dose, given the
available formulation. We administered 1000mgm
 2 gemcitabine
in a 30-min intravenous infusion on days 8 and 15 of each cycle.
The cycle was repeated every 21 days.
The dose of S-1 was not adjusted for toxicity, because
reducing dose of 30mgm
 2 twice daily S-1 could not maintain
effective blood concentration as 5-FU and the synergistic activity
of gemcitabine and 5-FU derived from S-1 was weakened.
Similarly, the dose of infusional 5-FU was fixed, and the dose of
gemcitabine was adjusted for toxicity in the report of phase I/II
study of gemcitabine combined infusional 5-FU (Hidalgo et al,
1999).
Full doses of both drugs were given in cases with grade 0–1
toxicity. If grade 2 toxicity was observed the gemcitabine dose was
reduced to 800mgm
 2 on days 8 or 15. In cases of grade 3 toxicity,
gemcitabine administration was omitted. In cases of grade 4
toxicity, both drugs were stopped and adjourned for 1 week.
When grade 3 toxicity was observed in two consecutive cycles,
or when grade 4 toxicity was observed even once, 800mgm
 2
gemcitabine and 30mgm
 2 twice daily S-1 were administered for
subsequent cycles. When grade 3 or 4 toxicity was observed even at
those doses, further reduction to 600mgm
 2 gemcitabine and
30mgm
 2 twice daily S-1 were administered for subsequent cycles.
We abandoned this treatment when grade 3 or 4 toxicity was
observed at that dose.
Pretreatment and follow-up studies
Pretreatment evaluation consisted of baseline studies including
medical history, physical examination, WHO performance status
assessment, blood chemistries, urine analysis, electrocardiograms,
CA19-9 serum levels. Chest X-ray and abdominal computed
tomography (CT) were performed within the period of 2 weeks
before starting chemotherapy in order to accurately define the
extent of the disease and the target lesions. Measurable disease was
defined as a bidimensionally measurable lesion 10mm or more in
size on spiral CT scan. Patients were re-evaluated every two cycles
(i.e. every 6 weeks) and then every 2 months after the withdrawal
of the protocol. Blood cell counts were performed weekly during
treatment and serum chemistry before every new cycle.
The National Cancer Institute (NCI) Common Toxicity Criteria
(CTC) scale (version 2.0) was used to evaluate treatment-related
side effects.
Assessment of efficacy
All patients were included in efficacy measurements on an intent-
to-treat basis. Tumour responses were evaluated according to the
World Health Organization’s criteria (World Health Organization,
1979). A complete response (CR) was defined as the disappearance
of all clinical evidence of the tumour for a minimum of 4 weeks. A
partial response (PR) was defined as a 50% or greater reduction in
the sum of the products of two perpendicular diameters of all
measurable lesions for 4 weeks or longer without any evidence of
new lesions. Stable disease (SD) was defined as less than a 50%
reduction or less than a 25% increase in the sum of the products of
the two perpendicular diameters of all lesions for 4 weeks or longer
without any evidence of new lesions. Progressive disease (PD) was
defined as an increase of 25% or more in the sum of the products
of two perpendicular diameters of all lesions, the appearance of
any new lesion, or deterioration in clinical status that was
consistent with disease progression. To assess objective response,
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spatients were evaluated every two cycles (i.e. every 6 weeks) by
three independent radiologists
The time to progression was measured from entry into the trial
up to the time when progression or death without evidence of
progression was observed.
Overall survival was estimated from the date of first treatment to
death or last follow-up visit.
Statistics
The number of patients required for the study was determined
according to the optimal two-stage design. Threshold response rate
and expected response rate were 10 and 30%, respectively. The
sample size of this trial was 29 patients (a- and b-error
probabilities 0.05 and 0.2, respectively). Time-related parameters
were analysed using Kaplan–Meier on an intention-to-treat
analysis.
RESULTS
All 33 patients with APC were registered between September 2003
and February 2005. Of 33 patients, 28 had liver metastasis, six had
lung metastasis and one presented with peritoneal carcinomatosis
and massive ascites only (Table 1). Although eligibility criteria
included patients who had a previous history of cancer treatment
(tumour resection, chemotherapy, immunotherapy, or radio-
therapy) before entry into the study, in actuality no patients had
previously received such treatment.
A total of 278 cycles (median 8, range 1–20) were administered.
Eleven patients (33%) received full dose intensity (Table 2).
A total of 22 patients (67%) observed grade 2 or more toxicity
needed dose reductions of administration of gemcitabine at least
once. However, 13 out of these patients could continue this
combination regimen at preplanned dose of 1000mgm
 2 of
gemcitabine from the subsequent cycles. The other nine (27%)
patients still continued at reduced dose of gemcitabine for the
subsequent cycles. Thus, 24 (73%) of all 33 patients did not require
one or more step of dose reduction of administration of
gemcitabine for all cycles.
Efficacy and survival
Results are shown in Table 3. An overall objective response was
observed in 16: one CR and 15 PR, and the overall response rate
was thus 48% (95% confidence interval (CI), 33–65%). Although
early discontinuation of treatment before the first evaluation was
caused by early progression in two patients, all responses were
confirmed 1 month later. Progressive disease was observed in eight
patients (24%) including the two patients.
Median time to progression was 5.4 months (95% CI, 2.5–8.4
months). Overall survival was 12.5 months (95% CI, 5.9–19.1
months). The Kaplan–Meier estimate of survival is shown in
Figure 1. The 1-year survival rate was 54% (95% CI, 36–72%).
Overall, at the time of the last analysis, 20 patients had died, all of
them due to progression of disease.
Toxicity
Maximum toxicity data for the 33 patients during all cycles of this
chemotherapy are listed in Table 4. The National Cancer Institute/
Common Toxicity Criteria grade 3 or 4 neutropenia, thrombocy-
topenia and anaemia were observed in 55, 15 and 9% of the
patients, respectively, including two cases of febrile neutropenia;
relevant grade 3 or 4 nonhaematological toxicities consisted of
anorexia, nausea, vomiting and diarrhoea but were very limited.
Table 1 Patient characteristics
Median age (range) 61 (45–73)
Gender No. of patients (%)
Male 21 (64)
Female 12 (36)
ECOG PS
0 11 (33)
1 20 (61)
2 2 (6)
Stage
Locally advanced 0
Metastatic 33 (100)
Prior therapy
Tumour resection 0
Radiotherapy 0
Chemotherapy 0
Sites of metastatic disease
a
Liver 28 (85)
Lung 6 (18)
Peritoneum 1 (3)
aSome were overlapping. ECOG¼Eastern Cooperative Oncology Group.
Table 2 Duration of administration and dose intensity of gemcitabine
No. of patients 33
No. of cycles
Total 278
Median 8
Range 1–20
Relative dose intensity of gemcitabine
Average 0.81
Median 0.90
Range 0.43–1.0
Table 3 Tumour response
Response
No. of patients CR PR SD PD Response rate (%)
33 1 15 9 8 48 (95% CI: 33–65%)
CR¼complete response; PR¼partial response; SD¼stable disease; PD¼progres-
sive disease.
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Figure 1 Overall survival curve for all 33 patients. Of 33 patients, 13 are
still alive. Median survival time was 12.5 months (95% CI, 5.9–19.1
months). One-year survival rate was 54% (95% CI, 36–72%).
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sAlthough a reduction of administration of gemcitabine was needed
in two-thirds of the patients in this study because of grade 3 or 4
neutropenia, it was possible to limit grade 3 or 4 neutropenia
during all cycles to 18% by reducing the quantity of administration
of gemcitabine in subsequent cycles. There was no patient who
gave up treatment because of neutropenia. There were two patients
who stopped treatment because of interstitial pneumonia.
Although grade 1 or 2 rash was observed in 79% of the patients
for the first cycle, it had improved by the preventive administra-
tion of 4 or 8mg dexamethasone before administration of
gemcitabine for subsequent cycles.
DISCUSSION
Although the current standard regimen for patients with APC
consists of single-agent gemcitabine, the objective responses are
low and the median survival benefit is modest in comparison with
5-FU alone. Owing to the activity of gemcitabine, a variety of
studies have now assessed its activity in combination with other
chemotherapy or novel agents. These studies have shown varying
degrees of success, with no combination showing clear evidence of
significantly superior activity.
Preliminary favourable results of S-1 in patients with APC have
been reported in Japanese early phase II study and late phase II
study (Furuse et al, 2005; Ueno et al, 2005). As yet, the
combination regimen of S-1 and gemcitabine for patients with
APC has not been investigated. We previously performed a phase I
study to evaluate the safety of treatment combining gemcitabine
with S-1 to determine the MTD of each drug in patients with APC
(Nakamura et al, 2005). That study indicated that the recom-
mended dose was 30mgm
 2 twice daily of S-1 given orally for 14
consecutive days and 1000mgm
 2 gemcitabine given on day 8 and
15, and that the cycle should be repeated every 21 days. The main
grade 3–4 toxicities observed during first cycle were neutropenia
(33%), anaemia (10%), thrombocytopenia (14%) and anorexia
(10%). Responses were one CR (5%) and nine PR (43%) among 21
patients. This combination was well tolerated and showed
outstanding antitumuor activity. Therefore, we chose to use this
regimen in a phase II study in patients with MPC.
This treatment administration as well as the tolerance profile
can be considered as satisfactory regarding the toxicities observed
although a reduction of administration of gemcitabine was
required in two-thirds of the patients. Myelosuppression,
especially neutropenia, frequently seen in the combination
of continuous infusion 5-FU and gemcitabine, was predicted
as the main toxicity of this study. The incidence of grade
3 or 4 neutropenia was greater than that of other toxicities,
but, the incidence of gastrointestinal toxicity during all cycles
was low.
Our efficacy results compare well with the other combination
regimen in pancreatic cancer although it is difficult to compare
phase II studies. Our response rate (48%) was much higher than
that observed in gemcitabine combined with infusional 5-FU
(19%) (Hidalgo et al, 1999) and in gemcitabine combined with
capecitabine (19%) (Hess et al, 2003) or UFT (16%) (Feliu et al,
2000), which is also an oral prodrug of 5-FU, like S-1. Moreover,
the median survival (12.5 months) and 1-year survival rate (54%)
were favourable notwithstanding all patients in this study having
distant metastatic disease.
Moreover, oral administration of S-1, which eliminates the cost
and inconvenience of continuous infusion of 5-FU, requiring
special pumps and catheters, with their potential risks of infection
and thrombosis, also contributes to fewer hospital visits during
this outpatient treatment. In fact, 31 of all 33 patients were treated
at outpatient clinics. These results indicated that the combination
at the recommended doses selected in this study is quite feasible in
the outpatient treatment setting.
In conclusion, the results of this study demonstrate the
tolerability and effectiveness of gemcitabine combined with oral
S-1 in patients with APC. The toxicities observed in this study were
mainly haematologic, with mild nonhaematologic toxicity. An
encouragingly high response rate was observed. This result is very
promising, but the survival benefit in comparison with gemcita-
bine monotherapy needs to be confirmed in a future randomised
clinical trial.
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